Jonna Frasor

Regulation of nuclear receptor transcriptional activity by a novel DEAD box RNA helicase (DP97).

Prolactin regulation of estrogen receptor expression.

Response-specific and ligand dose-dependent modulation of estrogen receptor (ER) alpha activity by ERbeta in the uterus.

Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype.

Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells.

Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) alpha or ERbeta in human osteosarcoma cells: distinct and common target genes for these receptors.

Therapeutic targeting in the estrogen receptor hormonal pathway.

Distinctive actions of membrane-targeted versus nuclear localized estrogen receptors in breast cancer cells.

Estrogen down-regulation of the corepressor N-CoR: mechanism and implications for estrogen derepression of N-CoR-regulated genes.

Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells.

Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome.

Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation.

Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene.

Synergistic up-regulation of prostaglandin E synthase expression in breast cancer cells by 17beta-estradiol and proinflammatory cytokines.

Estrogenic effects of herbal medicines from Costa Rica used for the management of menopausal symptoms.

Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer.

Estrogenic and progestagenic effects of extracts of Justicia pectoralis Jacq., an herbal medicine from Costa Rica used for the treatment of menopause and PMS.

Proinflammatory cytokines enhance estrogen-dependent expression of the multidrug transporter gene ABCG2 through estrogen receptor and NF{kappa}B cooperativity at adjacent response elements.

Estrogen promotes breast cancer cell survival in an inhibitor of apoptosis (IAP)-dependent manner.

The stimulation of HSD17B7 expression by estradiol provides a powerful feed-forward mechanism for estradiol biosynthesis in breast cancer cells.

An integrated bioinformatics approach identifies elevated cyclin E2 expression and E2F activity as distinct features of tamoxifen resistant breast tumors.

CBP mediates NF-κB-dependent histone acetylation and estrogen receptor recruitment to an estrogen response element in the BIRC3 promoter.

Minireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers.

14-3-3ζ as a predictor of early time to recurrence and distant metastasis in hormone receptor-positive and -negative breast cancers.

Growth hormone potentiates 17β-estradiol-dependent breast cancer cell proliferation independently of IGF-I receptor signaling.

NFκB affects estrogen receptor expression and activity in breast cancer through multiple mechanisms.

A novel aspirin prodrug inhibits NFκB activity and breast cancer stem cell properties.

Dimethyl Fumarate Inhibits the Nuclear Factor κB Pathway in Breast Cancer Cells by Covalent Modification of p65 Protein.

Correlative Analysis of miRNA Expression and Oncotype Dx Recurrence Score in Estrogen Receptor Positive Breast Carcinomas.

Full antagonism of the estrogen receptor without a prototypical ligand side chain.